Merdury Biopharmaceutical Corporation (TPEX: 6932)
Health Care · Pharmaceuticals · TW
NT$7.04
+15.22% today · +25.9% 1Y
Merdury Biopharmaceutical Corporation (TPEX: 6932) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $94.16M and employs 21 people.
Over the last twelve months the share price has gained 25.9%, trading between 4.71 and 12.20.
Tweenvest scores Merdury Biopharmaceutical Corporation across four factors: quality 43/100, value 36/100. Its strongest factor is quality.
6932 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $94.16M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.12
- Dividend yield
- —
- Beta (5Y)
- -1.15
- 52-week high
- NT$12.20
- 52-week low
- NT$4.71
- Avg volume (3M)
- —
- Shares outstanding
- 427.65M
- Employees
- 21
- Next earnings
- —
About Merdury Biopharmaceutical Corporation
Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury Biopharmaceutical Corporation is dedicated to creating innovative pharmaceutical solutions for medical conditions currently lacking adequate treatment options. A cornerstone of their strategy is the proprietary StackDose platform, an advanced drug development system designed to formulate novel medication delivery methods. This platform facilitates precisely timed drug release, targeted absorption at specific locations within the body, and flexible dosage modifications. The primary objective of StackDose is to significantly boost the bioavailability of active pharmaceutical ingredients, leading to a reduction in required drug dosages and fewer adverse effects. Their development pipeline currently addresses a variety of ailments, such as erectile dysfunction, pulmonary hypertension, sleep disturbances, benign prostatic hyperplasia, angina, migraines, hypertension, and pain management.
- ISIN
- TW0006932007
- Founded
- 2019
- Listed since
- Dec 23, 2022
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| The Jordanian Pharmaceutical Manufacturing Company - Public Shareholding CompanyASE: JPHM | $97.38M | JD1.52 | -1.30% |
| SAMSUNG PHARM. Co., LTD.KOSE: A001360 | $96.33M | ₩1,376.00 | -3.98% |
| Fusen Pharmaceutical Company LimitedSEHK: 1652 | $95.62M | HK$1.02 | +9.73% |
| Pak Fah Yeow International LimitedSEHK: 239 | $94.91M | HK$2.39 | -2.45% |
| Unité de Fabrication des Médicaments S.ABVMT: UMED | $93.89M | DT8.77 | -0.34% |
| PT Merck TbkIDX: MERK | $93.89M | Rp3,750.00 | -1.06% |
| AlzeCure Pharma AB (publ)OM: ALZCUR | $93.23M | Skr6.80 | +0.59% |
| Rani Therapeutics Holdings, Inc.NasdaqGM: RANI | $92.22M | $0.80 | +0.88% |
Figures last refreshed Oct 11, 2026.